title: Comparison of long-term (10 years) immunogenicity of two- and three-dose regimens of a combined hepatitis A and B vaccine in adolescents.
abstract: 300 adolescents aged 12-15 years were randomised (1:1) into two groups to compare the long-term (10 years) immunogenicity profile of two doses of an Adult formulation [Group HAB_2D: 150; 0-6 months] vs. three doses of a Paediatric formulation [Group HAB_3D: 150; 0-1-6 months] of a combined hepatitis A and B (HAB) vaccine. At Year 10, anti-HAV seropositivity rate was 100% in both groups, while 85.9% and 85.1% subjects in the HAB_2D and HAB_3D groups, respectively, had anti-HBs antibody concentrations > or =10 mIU/mL. The anti-HAV antibody GMCs (HAB_2D: 429.3 mIU/mL; HAB_3D: 335.5 mIU/mL) and anti-HBs antibody GMCs (HAB_2D: 50.6 mIU/mL; HAB_3D: 60.1 mIU/mL) were similar in both groups. No vaccine-related serious adverse events were reported. Hence, with respect to long-term antibody persistence, the two-dose schedule of the combined HAB vaccine Adult formulation is an effective alternative to the conventional three-dose schedule of the Paediatric formulation in adolescents.
authors.affiliation: Vaccination and Travel Medicine Centre, Bratrí Stefanů 895, 500 03 Hradec Králové, Czech Republic. jiri.beran@vakcinace.cz
authors.forename: Jiri
authors.initials: J
authors.lastname: Beran
authors.forename: Diane
authors.initials: D
authors.lastname: Kervyn
authors.forename: Veronika
authors.initials: V
authors.lastname: Wertzova
authors.forename: Lenka
authors.initials: L
authors.lastname: Hobzova
authors.forename: Petr
authors.initials: P
authors.lastname: Tichy
authors.forename: Sherine
authors.initials: S
authors.lastname: Kuriyakose
authors.forename: Maarten
authors.initials: M
authors.lastname: Leyssen
authors.forename: Jeanne-Marie
authors.initials: JM
authors.lastname: Jacquet
mesh_terms: D000293:Adolescent; D005260:Female; D005500:Follow-Up Studies; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control; D035922:Hepatitis A Antibodies / Q000097:blood; D022362:Hepatitis A Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000097:blood; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D017778:Vaccines, Combined; C433226:twinrix